TELZIR TABLET
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
05-07-2019
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
FOSAMPRENAVIR (FOSAMPRENAVIR CALCIUM)
Inapatikana kutoka:
VIIV HEALTHCARE ULC
ATC kanuni:
J05AE07
INN (Jina la Kimataifa):
FOSAMPRENAVIR
Kipimo:
700MG
Dawa fomu:
TABLET
Tungo:
FOSAMPRENAVIR (FOSAMPRENAVIR CALCIUM) 700MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
60
Dawa ya aina:
Prescription
Eneo la matibabu:
HIV PROTEASE INHIBITORS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0150429001; AHFS:
Idhini hali ya:
APPROVED
Idhini ya tarehe:
2009-12-08
Tabia za bidhaa
_ _
_Page 1 of 55_
PRODUCT MONOGRAPH
PR
TELZIR
Fosamprenavir tablets 700 mg
(as fosamprenavir calcium)
Fosamprenavir oral suspension 50 mg/mL
(as fosamprenavir calcium)
Antiretroviral Agent
ViiV Healthcare ULC
245, boulevard Armand-Frappier
Laval, Quebec
H7V 4A7
Date of Revision:
July 5, 2019
Submission Control No.: 226294
© 2019 ViiV Healthcare group of companies or its licensor.
Trademarks are owned by or licensed to the ViiV Healthcare group of
companies.
_ _
_Page 2 of 55_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................6
ADVERSE REACTIONS
..................................................................................................10
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND ADMINISTRATION
..............................................................................28
OVERDOSAGE
................................................................................................................30
ACTION AND CLINICAL PHARMACOLOGY
............................................................30
STORAGE AND STABILITY
..........................................................................................34
SPECIAL HANDLING INSTRUCTIONS
.......................................................................34
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................34
PART II: SCIENTIFIC INFORMATION
...............................................................................36
PHARMACEUTICAL INFORM
Soma hati kamili
